Catching Them Early: Framework Parameters and Progress for Prenatal and Childhood Application of Advanced Therapies

Author:

Lederer Carsten W.ORCID,Koniali Lola,Buerki-Thurnherr Tina,Papasavva Panayiota L.ORCID,La Grutta StefaniaORCID,Licari AmeliaORCID,Staud FrantisekORCID,Bonifazi DonatoORCID,Kleanthous Marina

Abstract

Advanced therapy medicinal products (ATMPs) are medicines for human use based on genes, cells or tissue engineering. After clear successes in adults, the nascent technology now sees increasing pediatric application. For many still untreatable disorders with pre- or perinatal onset, timely intervention is simply indispensable; thus, prenatal and pediatric applications of ATMPs hold great promise for curative treatments. Moreover, for most inherited disorders, early ATMP application may substantially improve efficiency, economy and accessibility compared with application in adults. Vindicating this notion, initial data for cell-based ATMPs show better cell yields, success rates and corrections of disease parameters for younger patients, in addition to reduced overall cell and vector requirements, illustrating that early application may resolve key obstacles to the widespread application of ATMPs for inherited disorders. Here, we provide a selective review of the latest ATMP developments for prenatal, perinatal and pediatric use, with special emphasis on its comparison with ATMPs for adults. Taken together, we provide a perspective on the enormous potential and key framework parameters of clinical prenatal and pediatric ATMP application.

Funder

European Commission

Research and Innovation Foundation of Cyprus

EEA and Norway Grants

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference352 articles.

1. Advanced Therapy Medicinal Products: Overview|European Medicines Agencyhttps://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview

2. Advanced Therapy Classification|European Medicines Agencyhttps://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/advanced-therapy-classification

3. Guidelines Relevant for Advanced Therapy Medicinal Products|European Medicines Agencyhttps://www.ema.europa.eu/en/human-regulatory/research-development/advanced-therapies/guidelines-relevant-advanced-therapy-medicinal-products

4. Marketing-Authorisation Procedures for Advanced-Therapy Medicinal Products|European Medicines Agencyhttps://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/marketing-authorisation-procedures-advanced-therapy-medicinal-products

5. Niraparib|Medicines|European Medicines Agencyhttps://www.ema.europa.eu/en/medicines?search_api_views_fulltext=cancer+niraparib

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3